TELO — Telo Genomics Income Statement
0.000.00%
Last trade - 00:00- CA$10.00m
- CA$8.75m
Annual income statement for Telo Genomics, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | — | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.24 | 1.07 | 2.11 | 2.82 | 2.71 |
| Operating Profit | -1.24 | -1.07 | -2.11 | -2.82 | -2.71 |
| Net Income Before Taxes | -1.24 | -1.07 | -2.11 | -2.82 | -2.71 |
| Net Income After Taxes | -1.24 | -1.07 | -2.11 | -2.82 | -2.71 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.24 | -1.07 | -2.11 | -2.82 | -2.71 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.24 | -1.07 | -2.11 | -2.82 | -2.71 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.045 | -0.027 | -0.036 | -0.047 | -0.038 |